<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455167</url>
  </required_header>
  <id_info>
    <org_study_id>14-0919</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02455167</nct_id>
  </id_info>
  <brief_title>Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis</brief_title>
  <official_title>Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1,&#xD;
           cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin&#xD;
           (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV).&#xD;
&#xD;
        2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV)&#xD;
           treatment using a new test of liver function, HepQuant-SHUNT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will quantify hepatic improvement and antiviral efficacy of the open-label&#xD;
      interferon-free combination of 12 weeks of simeprevir (SMV, Simeprevir), sofosbuvir (SOF,&#xD;
      Sofosbuvir), and ribavirin (RBV) in patients with HCV genotype 1 infection and early&#xD;
      decompensation of cirrhosis. Early decompensation is defined by clinical complications or&#xD;
      laboratory deterioration but with a model for end-stage liver disease (MELD) score of 10 or&#xD;
      less.&#xD;
&#xD;
      The primary objective of this trial is determination of hepatic functional improvement as&#xD;
      measured by the HepQuant (HQ) test during and after&#xD;
      Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV). Standard laboratory tests, clinical models&#xD;
      (MELD, CTP), liver biopsy, hepatic venous pressure gradient (HVPG), and other imaging tests&#xD;
      are insensitive, invasive, or nonspecific.&#xD;
&#xD;
      They may not adequately assess the liver's improvement after viral eradication. In contrast,&#xD;
      HepQuant (HQ) tests (Systemic Hepatic Filtration Rate (HFR), Portal HFR, SHUNT,single point&#xD;
      cholate concentration (STAT), and DSI) are noninvasive, sensitive, specific, and target an&#xD;
      endogenous function, the hepatic uptake of cholate. HQ tests uses serum sampling over a time&#xD;
      period of up to 90 minutes to quantify the systemic circulation, portal circulation, and&#xD;
      portal-systemic shunt and to derive a disease severity index (DSI) in intact human subjects.&#xD;
      The primary endpoint in this treatment trial will be improvement in hepatic function measured&#xD;
      by HepQuant (HQ) tests that occurs during and after successful&#xD;
      Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to low accrual and availability of other treatment options&#xD;
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 18, 2016</completion_date>
  <primary_completion_date type="Actual">July 18, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was &quot;Not Detected&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HCV positive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprivir (SMV)</intervention_name>
    <description>Experimental Single arm study. All participants will get the same treatment.</description>
    <arm_group_label>HCV positive group</arm_group_label>
    <other_name>Olysio (Simeprivir);</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir (SOF)</intervention_name>
    <description>Experimental Single arm study. All participants will get the same treatment.</description>
    <arm_group_label>HCV positive group</arm_group_label>
    <other_name>Solvaldi (Sofosbuvir);</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Experimental Single arm study. All participants will get the same treatment.</description>
    <arm_group_label>HCV positive group</arm_group_label>
    <other_name>Virazole (Ribavirin);</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HCV genotype 1 infection (all subtypes and Q80K a type of mutation are allowed), and&#xD;
             have been approved by a third party payer for the FDA-approved combination of&#xD;
             sofosbuvir (SOF) plus ribavirin. The study drug, simeprevir (SMV)&#xD;
&#xD;
          2. Biopsy proven cirrhosis, or clinical cirrhosis with APRI (AST to Platelet Ratio Index&#xD;
             to determine clinical cirrhosis)&gt; 2, Fibrotest &gt; 0.75, or Fibroscan &gt; 12.5 Results&#xD;
             Stiffness (kPa).&#xD;
&#xD;
          3. MELD 10 or less&#xD;
&#xD;
          4. Expected survival without liver transplantation of &gt;1 year&#xD;
&#xD;
          5. Patients with Hepatocellular carcinoma (HCC) are included as long as disease MELD is&#xD;
             10 or less, and anticipated time to transplant is &gt;1 year. An example, might be a&#xD;
             patient with a subcentimeter HCC who is undergoing serial imaging to document tumor&#xD;
             growth to tumor diameter &gt;2 cm prior to listing for transplantation (in order to&#xD;
             secure MELD exception). In this case, there could be a time lapse of 3 months or more&#xD;
             while monitoring tumor growth, and a further time lapse of 9 months or more until the&#xD;
             time of transplantation.&#xD;
&#xD;
          6. Patients with TIPS or Portal Vein Thrombosis may be included. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Known hypersensitivity or serious adverse reaction to any of the study drugs&#xD;
&#xD;
          3. Age &lt;18 or &gt;80 years&#xD;
&#xD;
          4. Pregnancy as determined by subject reporting and urine dipstick testing at screening.&#xD;
&#xD;
          5. Other underlying chronic liver disease - examples that would exclude a patient from&#xD;
             participating include but are not limited to nonalcoholic liver disease, alcoholic&#xD;
             liver disease, hepatitis B, hemochromatosis, and autoimmune liver disease.&#xD;
&#xD;
          6. Serious other underlying medical condition - examples include but are not limited to&#xD;
             unstable cardiovascular, coronary, or pulmonary disease including right and left sided&#xD;
             heart failure, active malignancy other than HCC, or serious infection.&#xD;
&#xD;
          7. Estimated creatinine clearance &lt; 30 mL min-1 1.73 m2 surface area (BSA)&#xD;
&#xD;
          8. Hemoglobin &lt;10 g/dL&#xD;
&#xD;
          9. Neutrophils &lt;500 /μL&#xD;
&#xD;
         10. Platelets &lt;50,000 /μL&#xD;
&#xD;
         11. Bilirubin &gt;4 mg/dL&#xD;
&#xD;
         12. Albumin &lt; 2.8 g/dL&#xD;
&#xD;
         13. Blood Clotting: International Normalised Ratio (INR) &gt; 2&#xD;
&#xD;
         14. MELD &gt;10&#xD;
&#xD;
         15. Child-Turcotte-Pugh class B or C; or, CTP score &gt;7&#xD;
&#xD;
         16. Conditions that would affect the absorption of orally administered cholate used in the&#xD;
             HepQuant® test - such as, extensive intestinal resection, diabetic gastroparesis, and&#xD;
             ileal disease or resection.&#xD;
&#xD;
         17. Concomitant use of both beta-blocker and ACE inhibitor&#xD;
&#xD;
         18. Subjects taking any other medications with significant drug drug interactions related&#xD;
             to the study medications (sofosbuvir, simeprevir, or ribavirin) who cannot discontinue&#xD;
             or substitute that medication, will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Wieland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver (Leprino Building)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC; HALT-C trial group. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther. 2007 Aug 1;26(3):401-10.</citation>
    <PMID>17635375</PMID>
  </results_reference>
  <results_reference>
    <citation>Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC; Halt-C Trial Group. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther. 2008 May;27(9):798-809. doi: 10.1111/j.1365-2036.2008.03639.x. Epub 2008 Feb 7.</citation>
    <PMID>18266997</PMID>
  </results_reference>
  <results_reference>
    <citation>Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther. 2009 Mar 1;29(5):589-601. doi: 10.1111/j.1365-2036.2008.03908.x. Epub 2008 Dec 1.</citation>
    <PMID>19053983</PMID>
  </results_reference>
  <results_reference>
    <citation>Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993 Oct;22(4):520-5.</citation>
    <PMID>8213790</PMID>
  </results_reference>
  <results_reference>
    <citation>Shrestha R, McKinley C, Showalter R, Wilner K, Marsano L, Vivian B, Everson GT. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl Surg. 1997 Mar;3(2):166-73.</citation>
    <PMID>9346731</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007 Nov;102(11):2589-600. Epub 2007 Sep 10. Review.</citation>
    <PMID>17850410</PMID>
  </results_reference>
  <results_reference>
    <citation>Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther. 2007 Jul 15;26(2):141-8. Review.</citation>
    <PMID>17593061</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <results_first_submitted>August 16, 2021</results_first_submitted>
  <results_first_submitted_qc>August 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 participants screen-failed after enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HCV Positive Group</title>
          <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HCV Positive Group</title>
          <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="40" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation</title>
        <description>Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was &quot;Not Detected&quot;.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HCV Positive Group</title>
            <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation</title>
          <description>Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was &quot;Not Detected&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline</title>
        <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HCV Positive Group</title>
            <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline</title>
          <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks</title>
        <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HCV Positive Group</title>
            <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks</title>
          <description>Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" lower_limit="7" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HCV Positive Group</title>
          <description>A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.&#xD;
Simeprivir (SMV): Experimental Single arm study. All participants will get the same treatment.&#xD;
Sofosbuvir (SOF): Experimental Single arm study. All participants will get the same treatment.&#xD;
Ribavirin (RBV): Experimental Single arm study. All participants will get the same treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Protocol deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amanda Wieland, MD</name_or_title>
      <organization>University of Colorado Denver | Anschutz</organization>
      <phone>3037241111</phone>
      <email>clinicalresearchsupportcenter@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

